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Abstract: The influence of microorganisms growing as sessile communities in a large 
number of human infections has been extensively studied and recognized for 30–40 years, 
therefore warranting intense scientific and medical research. Nonetheless, mimicking the 
biofilm-life style of bacteria and biofilm-related infections has been an arduous task. 
Models used to study biofilms range from simple in vitro to complex in vivo models of 
tissues or device-related infections. These different models have progressively contributed 
to the current knowledge of biofilm physiology within the host context. While far from a 
complete understanding of the multiple elements controlling the dynamic interactions 
between the host and biofilms, we are nowadays witnessing the emergence of promising 
preventive or curative strategies to fight biofilm-related infections. This review undertakes 
a comprehensive analysis of the literature from a historic perspective commenting on the 
contribution of the different models and discussing future venues and new approaches that 
can be merged with more traditional techniques in order to model biofilm-infections and 
efficiently fight them. 
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1. Introduction 
Pioneer studies by A.T. Henrici in the early 20th century [1] and later by J. W. Costerton and 
colleagues [2,3] have pointed to the existence of microorganism populations living on surfaces. 
Nowadays it is well accepted that, in most environments, microorganisms can switch from a  
free-living state to a sessile mode of life to form biofilms displaying specific properties. Among these 
specific properties is an enhanced tolerance to all sort of adverse conditions including desiccation and 
high concentrations of antimicrobial agents such as biocides, antibiotic and antifungal compounds [4–8]. 
Microorganisms growing and persisting on surfaces are problematic because, on one hand, they 
represent a source of contamination when present in a closed hospital environment and, on the other 
hand, when introduced into the body, they can develop on medical devices or tissues such as mucosa 
to form antimicrobial tolerant biofilms. N. Hoiby, J.W. Costerton and their collaborators were the first 
to suspect a direct correlation between bacteria growing as communities and persistent infections 
notably in the case of Pseudomonas aeruginosa colonizing the lungs of cystic fibrosis patients [9–14]. 
Since then, an increased awareness of the link between microorganisms growing on surfaces and 
development of human infections led to the estimation that 65% (Centers for Disease Control and 
Prevention/CDC [15]) to 80% (NIH [16]) of human infections were associated with biofilms (Figure 1). 
While difficult to precisely evaluate, such estimates reveal the importance of studying biofilms in 
order to better understand their specific properties and fight them. 
Figure 1. Most studied biofilm-related infections in humans. Adapted from [17]. 
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Development of simplified models started right after the demonstration of a link between sessile 
communities and human infections to study how bacteria, including pathogens, can form biofilms. 
Multiple in vitro models have emerged from scientists’ creativity, each of them especially adapted to 
observe biofilm formation of specific bacteria and within specific environments. The success of  
in vitro models but also their limitations, notably their failure to reproduce the host environment, led to 
a rapid development of multiple in vivo models ranging from surrogate non-mammalian models 
allowing high throughput analysis to more sophisticated models using rodents or higher animals such 
as dogs, pigs and monkeys. Interestingly, many of these models have been developed before clinicians 
and researchers realized that the modeled infection was indeed biofilm-related [18]. Importantly, 
because of justified ethical concerns, the use of mammalian in vivo models was early on restricted by 
legal regulations implying evaluation of scientific and medical benefits of the research but also taking 
into account animal welfare [19]. The protection of vertebrate animals therefore entails the evaluation 
of each project by ethics committees to confirm that they follow the “three R rule” edicted by Russel 
and Burch in 1959: Replace, Reduce and Refine [20]. This partially explains why in vitro and in vivo 
surrogate non-mammalian models are still heavily used and continue to reveal important insights about 
biofilm physiology and promising treatments for biofilm-related infections. 
The aim of this review is to present the various aspects of the development of biofilm-related 
infection models ranging from simple in vitro to complex in vivo models. We will focus on discussing 
which experimental results have already or are about to reach clinical studies in humans. This review 
will also discuss specific future approaches that start to be used and should help to model better 
biofilm-related infections. 
2. In vitro Biofilm Models 
Simplified in vitro models have been instrumental in addressing basic questions about biofilm 
formation, physiology and architecture. They offer a number of advantages such as a low cost, easy 
set-up, and amenability to high throughput screens. They generally mimic hallmarks of biofilm 
biology like different gradients of nutrients, gases and metabolic products, as well as high cell 
densities or production and release of extracellular matrix.  
A complete and comprehensive list of in vitro biofilm models is provided in Table 1 and see [21,22] 
for further information. Briefly, the different in vitro biofilm models can be classified in three  
distinct groups: 
(i) Closed or static models, in which there are limited nutrients and aeration. This includes some 
of the most popular and successful models, such as the colony biofilm model and microtiter 
plates [23,24]. In addition, these models enable direct rapid quantification of biofilm mass 
(via stains like crystal violet, safranin and congo red) or viable cells (XTT reduction assay). 
(ii) Open or dynamic systems. The principle of these models is similar to continuous cultures, in 
which spent culture consisting of wastes, metabolic byproducts, dispersed and dead cells are 
constantly replaced by fresh medium. These methods generally allow the control of 
environmental parameters such as shear forces, and have been therefore extensively used to 
study the physical and chemical resistance of biofilms. However, they are in most instances 
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less adapted to high throughput analysis and often demand specialized equipment and 
technical skills [22]. 
(iii) Microcosms are more sophisticated models that aim to closely mimic in situ conditions. They 
often include several bacterial species and use material from the studied environment, for 
instance, addition of hydroxyapatite and saliva to model dental biofilms [25], or covering 
abiotic surfaces with human cells in order to mimic an in vivo situation [26]. Theoretically, 
both open and closed systems could be turned into microcosms. Microcosms include more 
environmental parameters and take into consideration the complexity and heterogeneity of 
natural settings. 
Although often regarded as over-simplistic, in vitro models have greatly contributed to today’s 
knowledge of biofilm physiology. They are still largely used to study the role of different genes 
involved in biofilm formation and regulation processes, as well as other applied purposes such as to 
screen libraries of antimicrobial agents. Nevertheless, these models ignore important parameters like 
environmental factors, or more specifically when characterizing pathogenic biofilms, host factors and 
other biotic signals. 
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Table 1. In vitro and ex vivo biofilm models. 
Method Characteristics Advantages Uses of model References 
1. Static systems     
Colony Biofilm Colonies are grown over agar. 
Maintains basic biofilm characteristics  
like structured environment and chemical gradients. 
Reproducible and simple. 
Amenable to high throughput screening. 
Antibiotic susceptibility assessment 
Morphotypes observation essentially  
upon polysaccharides production 
[381,382] 
Microtiter plate Commonly used. 
Bacteria attach to well surfaces. 
Simple to run, 
Amenable to high throughput screening. 
Suited to molecular genetic tests. 
Evaluation of biofilm formation of strains,  
biofilm antibiotic tolerance and resistance,  
efficiency of antibiofilm/antimicrobial products 
[23,383] 
Biofilm Ring Test Immobilization of magnetic beads 
Results are automatized and analyzed by image analysis. 
Allows for a rapid monitoring  
of biofilm formation. 
Possibility to assess early adhesion events. 
Quick and automatic analysis. 
Does not involve washing and  
staining procedures. 
Evaluation of biofilm formation of strains [384] 
Calgary Biofilm Device Based on 96-well microtiter plate assay. 
Includes a lid with 96 pegs on which biofilms develop. 
Commercially available system. 
Pegs can be removed individually without opening 
the system, and hence avoiding contaminations. 
Consistent shear force across all pegs. 
Biofilm antibiotic resistance and tolerance,  
efficiency of antibiofilm/antimicrobial products. 
Study biofilm development over time. 
[385] 
2. Open systems     
Kadouri system Based on microtiter plate assay but  
with constant renewal of media. 
Minimum shear forces. 
Formation of mature biofilm in microtiter plate 
wells, meaning a big amount of biomass that can be 
later used for microarrays and proteomics 
Allows testing of multiple conditions and treatments. [386] 
Flow cell Flat walled transparent chambers  
irrigated by culture media under the microscope. 
Costly and expertise is needed. 
System is automatized and available for image analysis. 
Enables for non-destructive real-time biofilm 
observation (Allows single cell visualization). 
Excellent image quality 
Evaluation of biofilm formation of strains,  
biofilm antibiotic tolerance, efficiency of 
antibiofilm/antimicrobial products. 
[387] 
CDC Biofilm reactors Consists of eight polypropylene holders, accommodating 3 
coupons each over which bacteria adhere, suspended  
from a lid surrounded by media 
Commercially available system. 
Easy sampling at different time points 
Reliable system. 
Evaluation of biofilm formation, biofilm antibiotic  
resistance and tolerance. Test disinfectant efficiencies.  
Study biofilm development over time. 
[388] 
Microfermentors Chemostat-based 
Biofilms develop over a removable  
spatula composed of different materials 
Large mass of biofilm produced 
Allows microscopic, genetic and  
biochemical analysis 
Different shear forces can be applied 
Can be easily turned into a microcosm 
Easily converted into microcosms,by  
covering spatula with human cells. 
Evaluation of antibiotic effects and biofilm  
formation ability of strains. 
[389] 
Modified Robbins Device Ports sit in a linear array along a rectangular  
channel. In each port, a plug can be inserted. 
Sampling plugs can be removed  
and replaced aseptically 
Used to mimic throat conditions and evaluate the efficiency of 
different products in rubber tracheo-oesophageal prostheses 
[390] 
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Table 1. Cont. 
Method Characteristics Advantages Uses of model References 
Drip flow reactor Individual channels are introduced into polycarbonate blocks 
within which microscope slides may be placed. 
Biofilms are grown in an angled way. 
Low shear and high gas transfer. 
Allows for both solid-liquid and solid-air  
biofilm establishment. 
Wound biofilm model. Tested for antimicrobial 
efficiency  [391], bacteriophage reduction  
of biofilms and other antibiofilm strategies. 
Evaluation of disinfectant efficiencies.  
Study biofilm heterogeneity. 
[392] 
Microfluidic biochips Biochip is embedded in an aluminium block in which 
temperature is controlled. 
Has contactless dielectric microsensors. 
Non-invasive technique. 
Monitors dielectric changes of subcellular 
components within biofilm. 
Measures biofilm growth and  
development with sensitivity. 
Useful to study population dynamics and  
quantitative cell analysis. 
[393] 
Constant depth 
film fermenter 
Biofilms develop on polytetrafluoroethylene (PTFE) plugs. 
Biofilm growth and depth is limited. 
Excess biofilm is removed. 
Excess biofilm is removed (imitating mechanical 
biofilm removal like tongue effect or toothbrush). 
Specially suited to study oral biofilms.  
Tests of the effect of surface characteristic on biofilm 
formation. Antibiotic resistance tests. 
[394,395] 
Rotating Disc Reactor Teflon rotor holding several (6 to 24) coupons over which 
biofilms will form. Rotor is embedded with a magnetic stir 
bar on the bottom and driven by a stirrer. 
Liquid shear forces over the  
coupons can be varied. 
Evaluate antimicrobial and antifouling treatments. 
Also used to study multispecies biofilms. 
[396] 
BioFlux Device 96 individual microfluidic channels  
fed with a pneumatic pump. 
Shear can be controlled individually in each channel. 
Low cost in reagents and energy supply. 
High throughput analysis. 
Precise control of environmental conditions. 
Study of single cell behaviors  
within a community. 
High throughput screening. 
Evaluation of biofilm formation of strains,  
biofilm antibiotic tolerance and resistance, efficiency of 
antibiofilm/antimicrobial products 
[397] 
Annular reactors Based on two concentric cylinders; an outer static one which 
acts as the wall of the vessel and the inner rotating cylinder.  
Shear forces can be controlled. 
Removable test coupons. 
Evaluation of disinfection efficiencies.  
Study the effect of shear forces.  
Specially suited to study aquatic biofilms  
[398] 
Sorbarod devices (SBF) Sorbarod filter plugs with a cellulose  
matrix perfused with media. 
Easy set up. 
Substantial amounts of biomass. 
Growth rate control possible. 
Allows sampling of dispersed cells. 
Used to evaluate long-time effects of antibiotics. [399] 
Perfused (membrane) biofilm fermenter Cells are collected by pressure filtration in a cellulose acetate 
membrane. 
Filter is the inverted into the base of a modified fermentor 
Filter is the perfused with fresh medium 
Newly formed and loosely attached cells are eluted with 
spent medium. 
Allows growth-rate control bacteria or yeast 
Adherent bacterial biomass is constant and 
proportional to the limiting nutrient concentrations 
Used to evaluate antibiotic and fungicide efficiency [400] 
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Table 1. Cont. 
Method Characteristics Advantages Uses of model References 
3. Microcosms     
Reconstituted Human Epithelia (RHE) Biofilms form on top of human keratinocytes  
derived from buccal mucosa. 
Takes into account some host factors, such as 
receptor specificity. 
Human cells – bacteria biofilms interactions.  
Used to study oral biofilms. 
[401] 
Zürich Oral Biofilm-model Biofilms form on hydroxyapatite disposed in 24-well 
microtiter plates 
Can study population dynamics and antibiotic 
resistance and tolerance at the same time 
Semi high throughput 
Used to study oral biofilms. [402] 
Zürich Burn Biofilm-model Polymicrobial biofilms are grown on gauze discs of 
DermaPlast recovered by a protein pellicle  
disposed on 24-welled microtiter plates. 
Allows the study of structure of  
polymicrobial biofilms. 
High repeatability. 
Mimics biofilms development on burns.  
Suitable to assess antimicrobial efficiencies. 
[403] 
Endothelial Cells Under Flow model Biofilms forms on human microvascular endothelial 
cells attached to microscope slide, perfused with media, 
under an inverted fluorescent microscope. 
Has a continuous flow of nutrients. 
Biofilm development can be imaged  
and cells can be tracked. 
Takes into account shear forces in blood vessels. 
Biofilm formation and dynamics on  
blood vessels and valves. 
[404] 
Airway Epithelial cell Model Airway epithelial cells are disposed on  
collagen-coated membranes. 
Allows formation of air-liquid biofilm formation. Models chronic rhinosinusitis, cystic fibrosis 
and other biofilm-related pulmonary infections. 
[405] 
Multiple Sorbarod device (MSD) Modified SBF system with five replicate plugs. Allows for multiple replicates. Used to replicate oral microcosms,  
perfused with saliva and multispecies biofilms 
[406] 
Microfluidic Co-culture model Microfluidic channels covered with HeLa  
cells over which biofilms form. 
Analysis of host-bacteria interactions.  
Real-time visualization of biofilm development. 
Used to mimic gastrointestinal colonization.  
Human cells – bacteria biofilms interactions. 
[407] 
4. Ex vivo     
Root canal biofilms Extracted tooth are embedded in silicone putty and irrigated. Irrigation of dental surfaces. 
Allows imaging. 
Remove dental biofilms and root canal infections [408] 
Cardiac valve ex vivo model Use of excised porcine heart valve. Study initial bacteria and  
the valve tissue interactions. 
Adapted to imaging (field emission  
scanning microscopy). 
Evaluate progression of endocarditis [409] 
Candidiasis in vaginal mucosa Rabbit vaginas are placed in 6-well tissue culture plates. Optimal for microscopic evaluations  
(confocal and scanning). 
Model of candidiasis [27] 
RWV Bioreactor System able to grow 3D structures. 
Bubble-free aeration: 
Maintains cell polarity, differentiation  
and extracellular matrix production: 
Circumvents conventional monolayers limitations. 
Minimizes mechanical cell damage. 
Microgravity conditions are maintained. 
Has been used to model P. aeruginosa infection in 
lungs, Salmonella in gut and uropathogenic E. coli 
[410–412] 
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3. Ex vivo Biofilm Models 
Midway between in vitro and in vivo lie ex vivo models, in which tissues or organs are extracted 
from an organism (typically porcine or murine) and placed in an artificial environment for further 
analysis and experimentation. Often neglected, they allow for more controlled experimental conditions 
than in vivo models and can provide an alternative to living organisms in order to perform otherwise 
ethically questionable measurements and experiments. They can be particularly useful to image or 
analyze the progression of bacterial colonization of a given organ or tissue, such as tracheal 
epithelium, vaginal mucosa, kidneys or teeth [27–30]. They can also be used to assess different  
time-windows for effective treatment of biofilm infections [31]. Details of different ex vivo models are 
described in Table 1.  
4. Non-Mammalian in vivo Models 
Infection and pathogenesis is a continuous interplay between the host and microbes and between 
microbes themselves. These interactions can influence and determine the fate of infection and they are 
complex and dynamic, which makes it difficult to study them in a relevant manner in in vitro  
models [32]. As in vitro models offer a simplified vision of the environment, it is important to use 
adequate in vivo models to validate in vitro results as a first step to test hypothesis that could be later 
translated into higher organisms or clinical settings.  
In the past ten years, in order to overcome the practical difficulty associated with the use of 
mammalian models, non-mammalian models traditionally used to study development like the fruit fly, 
Drosophila melanogaster or the zebrafish, Danio rerio, have been adapted to study host-microbe 
interactions and immune system responses, notably related to colonization of the gut by biofilms [33]. 
Increasing awareness of biofilm-related infections has prompted these and other models discussed in 
Table 2 and Figure 2, to study tissue colonization, biofilm formation and the onset of pathogenesis. 
Many different models have been proposed, ranging from simple plant models such as Arabidopsis 
thaliana and Lemna minor, which were successfully used to correlate virulence and biofilm formation 
in pathogenic S. aureus and P. aeruginosa [34] to more complex invertebrates like Caenorhabditis 
elegans [35], D. melanogaster (Figure 2) [36–38] or the vertebrate zebrafish [39–41] (Table 2 and 
Figure 2). 
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Table 2. Non-mammalian in vivo models. 
Organism Size Generation 
time 
Temp. 
(°C) 
Immune system Follow-up of host 
infection 
Relevant Model Human Pathogens studied References 
Tetrahymena pyriformis 20 × 40 μm 7 hours 22–26 Unknown Real-time through 
bacterial fluorescent 
markers 
Biofilm grazing, 
Virulence and toxicity 
Klebsiella pneumoniae, Legionella pneumophila, 
Vibrio cholerae 
[413] 
Acanthamoeba sp. 15 to 35 μm 6–10 hours 19–25 Macrophage analog -- Biofilm grazing, 
Phagocytosis, 
intracellular survival 
L. pneumophila, Cryptococcus neoformans, Candida 
albicans, Methicillin-resistant Staphylococcus aureus 
(MRSA), V. cholerae 
[414] 
Dictyostellium discoideum 
(Slime mould) 
10–20 μm 4–12 hours 19–25 Macrophage analog Real-time through 
bacterial fluorescent 
markers 
Biofilm grazing, 
Phagocytosis, 
intracellular survival 
Pseudomonas aeruginosa, L. pneumophila, Listeria 
monocytogenes 
(intracellular pathogens) 
[415] 
Lemna minor (Duckweed) 2–5 mm ×  
1.5–3.5 mm 
1 week 28 Unknown ✗ Biofilm formation and 
virulence 
S. aureus, P. aeruginosa, Salmonella spp., Shigella 
spp., Yersinia spp. 
[34] 
Medicago sativa 
(Wounded alfalfa) 
Seedlings 3 months 30 Unknown ✗ Chronic bacterial lung 
infections,  
P. aeruginosa, Burkholdheria cepacia [416] 
Arabidopsis thaliana 
(Thale cress) 
1 to 20–25 cm 3 weeks 20–25 Analog pathways 
to MAPK 
✗ Biofilm formation and 
virulence 
Pseudomonas spp., S. aureus [417] 
Hirudo sp 
(Leach) 
15–40 mm (adult) -- 10–35 Unknown -- Biofilm competition 
and gut colonization 
Aeromonas spp. [418] 
Panagrellus redivivus 
(Sour paste nematode) 
1 mm × 50 μm 3–5 days 37 Innate immunity 
(Toll-like receptor, MAPK) 
-- Biofilm formation, 
virulence, gut 
colonization 
P. aeruginosa, Salmonella enterica, and S. aureus [419] 
Caenorhabditis elegans 
(Round worm) 
1 mm × 100 μm 4–7 days 22-27 Innate immunity 
(Toll-like receptor, MAPK) 
Real-time through 
bacterial fluorescent 
markers 
Biofilm formation, 
virulence, gut 
colonization 
Microbacterium nematophilum, Escherichia coli, 
Shigella flexneri, V. cholerae, Shewanella spp. Listeria 
spp., S. aureus, Streptococcus sp. 
[420] 
Galleria mellonella 
(Wax moth caterpillar) 
3 cm in length -- 30 Innate immunity 
(Toll-like receptor, MAPK, 
NFκB) 
-- Biofilm formation and 
virulence  
Pseudomonas spp., Proteus mirabilis, E. coli,  
Bacillus cereus 
Bacillus thuringiensis 
C. albicans, C. neoformans 
[421] 
Drosophila melanogaster 
(Fruit fly) 
3 mm 10 days 12-30 Innate immunity 
(Toll-like receptor, Imd, 
MAPK, NFκB) 
Real-time through 
fluorescent markers, 
LacZ fusions available 
Biofilm formation, 
virulence, gut 
colonization 
Wolbachia spp., Serratia marcescens, Erwinia spp., 
Pseudomonas entomophila, C. neoformans, Francisella 
novicida, L. monocytogenes, V. cholerae, C. albicans 
[422] 
Danio rerio 
(Zebrafish) 
3-5 mm (larvae) 
6-6.5 cm (adult) 
3–4 months 23-28 Adaptive and innate Real-time through 
fluorescent markers both 
on host and bacteria 
Biofilm formation, 
virulence, gut 
colonization 
Mycobacterium marinum, Oodinium, Microsporidia, E. 
coli, Pseudomonas spp., Salmonella spp. Vibrio spp. 
[423] 
1 As insects, they could also be used to model gut colonization and commensal-pathogen interaction. However, to the best of our knowledge, it has not yet been used with this objective. ✗: not possible;  
--: not described. 
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Figure 2. Non-mammalian in vivo models. A. Experimental settings. Drosophila 
melanogaster. Ten male fruit flies are selected and introduced in standard fly vials. A 
dilution of a Vibrio cholerae overnight culture to 5 * 10
8
 CFU/mL is used to impregnate a 
0.5-inch cellulose acetate plug placed at the bottom of each vial. Then, the vials are kept at 
24 °C with appropriate light-dark cycles. Fruit fly survival is monitored twice a day for 5 to 
7 days. B. Confocal microscopy image of D. melanogaster rectum papillae (oval structures) 
colonized by a V. cholerae (gfp-tagged, green) biofilm. Cell nuclei are stained in blue 
(DAPI staining). Images Credit: A. Purdy and P.I. Watnick Division of Infectious 
Diseases, Children’s Hospital, Boston, USA. Adapted from [38]. C. Experimental settings. 
Axenic zebrafish infection. After fertilization, eggs are immediately sterilized and kept in 
vented cap cell culture flasks in autoclaved mineral water at 28 °C. Starting at 4 dpf (days 
after fertilization), larvae are fed every 2 days with axenic Tetrahymena thermophila until 
day 15. For longer experiments, in addition to T. thermophila, larvae were fed axenic 
Artemia salina from 10 dpf onwards. Zebrafish larvae are infected 6 days after fertilization 
with 5 * 10
8
 CFU/mL of pathogen. Mortality can be easily followed on daily basis. 
Adapted from [41]. D. Confocal fluorescence pictures of larval intestine infected by the 
pathogen E. ictaluri (detected by immunofluorescence, red) 1 day after infection. Zebrafish 
cell nuclei are shown in blue (DAPI staining) and actin in green. Images Credit: J.P. 
Levraud and M. Frétaud, Institut Pasteur, Paris, France. 
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Non-mammalian models share advantages such as a rapid development leading to short generation 
time and are generally cheap to raise and perform experiments. In addition, most of these model 
organisms have their genome already sequenced and can be genetically manipulated, thus, offering the 
possibility to do genetics both on the bacteria and the host. In addition, their small size enables to 
maintain most of them in microtiter plates, which is useful to perform high throughput studies, some of 
which in an automated version [42]. This has already allowed successful screening for virulence  
genes [39,43–45], colonization and biofilm formation factors [34,46,47] or chemical libraries for 
antimicrobial compounds [48].  
Their reduced complexity for some pivotal systems linked to infection has actually been an 
advantage. For example, despite the simplicity of their immune system, these surrogate non-mammalian 
organisms have been useful to identify evolutionarily conserved host defense mechanisms and have 
shed light into universal immune mechanisms [49]. Additionally, the facility of generating axenic or 
gnotobiotic animal models has allowed simplifying host/pathogens and flora interactions studies. 
Recent research using an axenic zebrafish model has proven that increased biofilm forming ability of 
commensal bacteria can rescue larvae from Edwardsiella ictaluri-induced death [41]. 
Nevertheless, these models reached their limits when studying complex immune responses in 
relation to biofilm infection or using pathogens whose optimal growth temperature and expression of 
virulence factors are beyond the animal growth temperature. Moreover, due to the short lifespan and 
duration of experiments, these models seem unsuited to study chronic infections typically caused  
by biofilms. 
5. Tissue-Associated Biofilm Models 
While important information has been generated using in vitro and invertebrate in vivo models, the 
use of mammalian models that are closer to humans is required before considering going from bench 
to bedside. Therefore, many efforts have been made to closely mimic in higher organisms the 
occurrence of biofilm-related infections that allowed us to address diagnostic or therapeutic challenges 
(see Table 3).  
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Table 3. In vivo models of biofilm-related infections.  
Type of biofilm-related 
infection 
Type of model Animal Microorganisms 
Direct biofilm 
/chronic infection 
Technical details References 
Tissue-related infections       
CF lung infections Agar-bead based infection model 
Rats, mice, cats, 
guinea pigs and 
monkeys 
P.a, S.a, H.i and  
B. cenocepacia 
B Intratracheal route of infection [54–59] 
 
Seaweed alginate  
microsphere infection 
Rats, mice, 
guinea pigs 
P.a B Intratracheal route of infection [62–64] 
 Agar-bead based model Mice P.a B Intravenous injections [66,67,424,425] 
 CF model (CFTR-/- mice) 
Mice, pigs, 
ferrets 
P.a, S.a and B. cepacia B Agar-bead based intranasal route of infection [68,70,74,426] 
COPD associated infections COPD/emphysema Mice H.i B Intranasal route of infection [76] 
Diffuse panbronchiolitis Chronic diffuse panbronchiolitis Mice P.a CI Piece of intravenous catheter coated with P. aeruginosa [80–82] 
Urinary tract infections Murine cystitis model Mice E.c, K.p B Transurethral catheter for inoculating bacteria in bladder [89,91] 
 Rat model of chronic cystitis Rats E.c CI Transurethral catheter for inoculating bacteria in bladder [86] 
Chronic bacterial prostatitis 
Experimental model  
of chronic prostatitis 
Rats P.m, E.c CI Prostatic urethral injections [115,117,118] 
Urinary Stones or Struvites Rat model of urolithiasis Rats P.m, U. urealyticum B Foreign body like zinc disc or chalk in bladder [127,129,130,427] 
Pyelonephritis Urinary stone genesis model Rats P.m B Zinc discs in bladder [127] 
Intestinal Infections Intestinal colonization model Mice C. rodentium  Oral dosing of bacteria [141,142] 
 
Streptomycin-treated  
mouse model 
Mice E.c, Salmonella B Oral dosing of bacteria [138,140] 
Gall Bladder Infections Chronic infection model Mice Salmonella CI Oral infection [145–147] 
Chronic wounds infection 
Needle scratch model,  
Skin abrasion 
Mice MRSA B Scratch with 28 gauge needle on skin to damage epidermis [152] 
 Wound infection model Mice MSSA B 
Full-thickness wound is established through the panniculus carnosus on the 
back of animals 
[158] 
 Excisional wound model Mice S.a B Cuts made on the back of mice [156] 
 Ischemic wound model Rats P.a B Pressure-induced wounds [159] 
 Cutaneous wound healing model Rabbits P.a B Circular punch-wounds in ear [428] 
 Cutaneous porcine wound model Pigs S.a B 
Partial thickness wounds on paravertebral area using a modified 
electrokeratome 
[157] 
 Diabetic foot wound model Mice 
E.c, B. fragilis and C. 
perfringens 
B Leptin-receptor deficient mice injected in inner thigh [161] 
Infective endocarditis Catheter-induced IE Rabbits S.a B High inoculum of bacteria injected intravenously [164,166] 
 
Low-Grade bacteremia  
model of IE 
Rats L. lactis B Low-grade inoculum of bacteria injected intravenously [169] 
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Table 3. Cont. 
Type of biofilm-related 
infection 
Type of model Animal Microorganisms 
Direct biofilm 
/chronic infection 
Technical details References 
Chronic otitis media COM with effusion Gerbils H.i, S. pneumoniae B 
Injected percutaneously into the superior posterior chamber of the left middle 
ear 
[429] 
 Chinchilla Model of COM Chinchillas 
H.i, P.a, group A 
Streptococcus 
B Bacteria is injected bilaterally via a transbullar approach [183,186] 
 
Nonhuman primate  
model of COM 
Cynomolugus 
macaques 
P.a B Perforation of the tympanic membrane and inoculation of the middle ear [190] 
 COM Rats P.a B Intranasal inoculation using teflon cannula [191] 
 COM Mice S. pneumoniae CI Spontaneous OM development in plasminogen deficient mice [192] 
Chronic rhinosinusitis Chronic rhinosinusitis Rabbits S. pneumoniae CI 
Hole drilled into the dorsum of nose, cotton wool inserted and inoculated with 
10.8 bacteria 
[195] 
 Chronic rhinosinusitis Mice 
L. sakei, C. 
tuberculostearicum 
CI Intranasal inoculation [197] 
 
Experimental rhinosinusitis 
biofilm model 
Sheep S.a B Ostium occluded and bacteria instilled [198] 
Dental caries Experimental caries Hamsters S. mutans CI Oral inoculation [206] 
 Model of Cystic Fibrosis Mice S. mutans B Swabbing the oral cavity of CFTR knock out mice [205] 
 Model of periodontal disease Rats P. gingivalis B Topical administration of bacteria [207] 
Periodontitis Oral infection model Mice T. denticola, P. gingivalis CI Oral inoculation by gavage [207,223] 
 Experimental periodontitis Mice 
F. nucleatum, P. gingivalis, 
T. forsythia 
B Oral gavage using a feeding needle [222,224] 
 Experimental periodontitis Rabbits P. gingivalis B Oral inoculation [430,431] 
Osteomyelitis Chronic osteomyelitis Rabbits S.a CI Injection in tibial metaphysis into the intramedullar cavity [229] 
 Osteomyelitis model of biofilm Rabbits S.a B Injection in tibial metaphysis into the intramedullar cavity [231,232] 
 
Experimental chronic 
osteomyelitis 
Rats S.a CI Hole is drilled into the medullar cavity, bacteria are injected into the bone [233] 
 
Experimental model of 
osteomyelitis 
Mice S.a CI Bioluminescent strain of S. aureus is inoculated into the femurs of mice [234] 
Device related-infections       
Vascular Catheter CVC Rats S.e, S.a, C.a B 
Catheter tip in superior vena cava through jugular vein, tunneled 
subcutaneously and exits on the back. Use of restraint jacket 
[239,245,432] 
 CVC Rabbits S.e, S.a B 
Catheter tip in superior vena cava through jugular vein, tunneled 
subcutaneously and exits on the back. Use of restraint jacket 
[247,252,253] 
 
Totally implantable venous 
access port 
Rats S.a, S.e, P.a, E.c B 
Catheter tip in superior vena cava through jugular vein, tunneled 
subcutaneously and connected to a subcutaneous port  
[256] 
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Table 3. Cont. 
Type of biofilm-related 
infection 
Type of model Animal Microorganisms 
Direct biofilm 
/chronic infection 
Technical details References 
Urinary tract catheters Bladder glass bead (surgical) Rats E.c B 
Bead colonized by E. coli biofilm surgically inserted in the bladder. Urethra 
clamped 1h/day to reproduce vesico-ureteral reflux 
[260] 
 
Bladder pieces of catheter 
(surgical) 
Rats P.a B 
Surgical insertion of pieces of urinary catheter. Bacterial inoculation is made 
inside the bladder, after catheter insertion  
[261] 
   Mice E.c B   [262] 
 
Bladder pieces of catheter  
(non surgical) 
Rabbits P.a, P.m B 
Use of urethral catheter and/or metal stylet in order to transurethrally insert 
pieces of catheter inside the animal bladder 
[263,265] 
  Rats P.a B   [433] 
  Mice P.a, P.m, E.c, E. faecalis B   [264,266] 
 Externalized urethral catheter Rabbits E.c B 
Urethral catheter inserted and connected to a urine collector via a closed system 
in order to mimic an externalized system 
[269–271] 
  Sheep  B   [272] 
Orthopedic implants Foreign-body in tibia Rabbits S.a B 
Silicone rubber catheter inserted into the tibia and associated with sclerosing 
agent to induce aseptic necrosis 
[277,434] 
 Foreign-body in tibia Rabbits S.a B 
Titanium cylinder or bone cement inserted into the tibia. Bacterial inoculation 
up to 4 months after foreign-body placement 
[279,435] 
 Electrode inserted in tibia Rabbits S.e B 
S. epidermidis is injected inside tibia through a hole. A stainless steel electrode 
is inserted inside medullar cavity + bone cement  
[436] 
 
Devascularized bone  
and metal screws 
Rabbits  B 
A piece of diaphyseal radial bone is removed. Then, this devascularized bone is 
replaced inside the wound using metal screws  
[280] 
 Spinal device model Rabbits S.a B 
Partial laminectomy followed by a wire implantation of the transverse 
processes of different vertebra (T13, L3, L6) 
[437] 
 Titanium wire inside tibia Rats S.a B 
Insertion in the medullar canal of a long titanium wire. Before the insertion of 
the foreign-body, S. aureus inoculum is injected 
[282,283] 
 
Stainless steel pin inserted 
through tibia 
Mice S.a B 
Stainless steel pin incubated 20 minutes with bioluminescent S. aureus and then 
inserted transcortically through mice tibia  
[281,438] 
 Bone cement in tibia Dogs S.a B 
Removal of a cortical part of tibial metaphysis. Then, polymethylmethacrylate 
cement and S. aureus are inserted in bone pocket  
[284] 
 
Cylindrical device  
in femoral canal 
Dogs S.e, S.a, E.c B 
Cylindrical device (made of stainless steel, cobalt chromium, polyethylene or 
polymethylmetacrylate) inserted inside femoral canal 
[278] 
 Intramedullar nail  Dogs E.c, P.a B 
Mid-diaphyseal osteotomy and internal fixation with an intramedullar nail 
inoculated, before fixation, with E. coli and P. aeruginosa 
[439] 
 
Fracture fixation stainless steel 
plates 
Sheep S.a B 
Membranes colonized by S. aureus biofilms are positioned on stainless steel 
plates and drilled on a cortical surface of sheep tibia 
[440] 
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Table 3. Cont. 
Type of biofilm-related 
infection 
Type of model Animal Microorganisms 
Direct biofilm 
/chronic infection 
Technical details References 
Prosthetic joints 
Hemiarthroplasty and bone 
cement 
Rabbits E.c B 
Knee hemiarthroplasty and acrylic bone cement followed by intraarticular E. 
coli injection 
[287] 
 Total knee replacement Rabbits S.a B  [288] 
 Hip stainless steel prosthesis Rabbits S.a B  [441] 
 Silicone-elastomer implant Rabbits S.a B 
Partial knees arthroplasty using silicone-elastomer implants. At the end of 
surgical procedure, S. aureus is injected into the joint 
[286] 
 
Pin inside femur with the tip in 
the joint 
Mice S.a B 
Stainless steel pin is inserted inside the femoral canal and the distal end of the 
pin protrudes inside the joint space 
[289] 
Endotracheal tubes Ventilated sheep  Sheep Oral flora B 
Animals are intubated and ventilated for 24 to 96 hours before being sacrificed 
for endotracheal tubes analysis 
[293,297] 
 
Ventilated pig with  
induced pneumonia 
Pigs S.a B  [294] 
 Ventilated dog Dogs P.a B  [295] 
Vascular grafts Infrarenal aortic vascular graft  Dogs S.e B 
Implantation of dacron prosthesis colonized by S. epidermidis on the infrarenal 
aorta of a dog leading to a prosthetic graft infection 
[300,442,443] 
 Infrarenal aortic vascular graft  Pigs S.a B 
Surgical implantation in the infrarenal abdominal aorta of vascular grafts 
colonized by S. aureus 
[303] 
Tissue fillers Breast implants Pigs S.e B 
Each pig received up to 6 miniature silicone gel-filled implants into 
submammary pockets + inoculated with S. epidermidis 
[306,307] 
 Breast implants Rats S.a B  [444] 
Contact lenses 
Damaged cornea and  
contact lenses 
Mice Fusarium spp. B 
Fusarium spp. are grown as biofilm on silicone hydrogel contact lenses and 
mouse cornea are damaged by scratches or abrasion 
[311] 
Dental implants Titanium screw into hard palate Rats A. actinomycetemcomitans B Biofilm-inoculated titanium implants transmucosally placed into rat hard palate [315] 
 Intrabuccal splints and disks Humans Oral flora B 
A removable fixation system applied on the mandibular region, inside the 
mouth of healthy volunteers. On these splints, disks made of various surfaces 
can be placed to study biofilm formation 
[316] 
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Table 3. Cont. 
Type of biofilm-related 
infection 
Type of model Animal Microorganisms 
Direct biofilm 
/chronic infection 
Technical details References 
Subcutaneous models Tissue cage 
Mice, rats, 
hamsters, guinea 
pigs, ponies 
S.a, S.e, A. radicidentis B 
Rigid tubes, mostly made of teflon and perforated with holes, sealed at each 
end, possibly filled with glass bead and usually inserted in the flank of animal. 
Tissue cage fluid can be collected by percutaneous aspiration 
For review: [22] 
 Vascular catheter 
Mice, rats, 
rabbits 
S.e, S.a, E.c B 
Insertion of a 1-cm segment of vascular catheter in a subcutaneous space. At 
the end of the experiment, mice are euthanized, catheter segment is removed, 
vortexed in order to recover the biofilm 
For review: [22,243] 
 Cement disks Rabbits E.c B 
Acrylic bone cements shaped like disks and colonized by E. coli biofilm are 
surgically inserted into subcutaneous pockets on the back 
[329] 
 Pacing device Rabbits 
S.e, S. capitis, E. c and  
A. baumannii 
B 
Pacing device is inserted in subcutaneous pockets on the back of the animals. 
Bacterial contamination is made inside the pocket, at the end of the experiment 
[330] 
 Fabric to mimic cardiac valves 
Guinea pigs, 
mice, rabbits 
S.e, P.a B 
Various types of implants impregnated with antibiotics or not are incubated 
with a bacterial solution in order to allow biofilm formation. Afterwards, these 
devices are inserted into subcutaneous pockets 
[331,332,334] 
 Vascular grafts 
Hamsters, mice, 
rats 
S.e B 
Gore-tex implants colonized by S. epidermidis biofilm are inserted into 
subcutaneous pockets 
[335,336,445] 
 Polyethylene disks Mice, rabbits E.c, P.a B Subcutaneous implantation of polyethylene disks  [338] 
 Beads Rats S.a B 
Polymethylmethacrylate beads loaded or not with various compounds are 
inserted in subcutaneous space 
[339] 
 Surgical mesh Mice S.a B 
Insertion of resorbable or non resorbable surgical meshes colonized by S. 
aureus biofilm inside subcutaneous pockets 
[340,341] 
NOTE: B: biofilm, C.a: Candida albicans, CVC: Central venous catheter, CI: chronic infection, COPD: chronic obstructive pulmonary disease, COM: chronic otitis media, CF: cystic fibrosis, E.c: Escherichia 
coli, H.i: Haemophilus influenzae, IE: Infective endocarditis, K.p: Klebsiella pneumoniae, MRSA: methicillin-resistant S. aureus, MSSA: methicillin-susceptible S. aureus, P.m: Proteus mirabilis,  
P.a: Pseudomonas aeruginosa, S.a: Staphylococcus aureus, S.e: Staphylococcus epidermidis. 
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The role of biofilm in the pathophysiology of tissue-associated infection has been increasingly 
recognized in the past decades (Figure 1). Biofilm may develop after colonization of sterile or  
non-sterile tissue or mucosa by microorganisms or may take advantage of the prior alteration of 
resident commensal flora by antibiotics. 
5.1. Lung Infections 
5.1.1. Cystic Fibrosis (CF) Related Lung Infections 
CF disease is the result of a single gene mutation in cystic fibrosis transmembrane conductance 
regulator (CFTR) leading to a multitude of medical problems amongst which are pancreatic failures, 
alteration of mucosal secretions and of epithelial innate immune function in the lungs. However, the 
most challenging aspect of the disease is pulmonary infection that leads to 80–95% of respiratory 
failure by chronic bacterial infection and airway inflammation [50–52]. While previously suggested by 
Lam et al. and Hoiby et al., who showed the presence of matrix-embedded microcolonies of  
P. aeruginosa in chronically infected lungs [12,14], confirmation of the role of biofilms was provided 
by Singh et al., through identification of a specific quorum sensing signal signature [53]. 
Animal models used to mimic CF infected lungs can be broadly divided based on the route of 
infection chosen: intratracheal or intravenous. 
i. Intratracheal route: Cash et al., were the first to describe a rat model to establish P. aeruginosa 
chronic lung infection, lasting up to 1 month, by immobilizing bacteria in agar beads [54]. 
This model was later adapted to mice, guinea pigs, cats, monkeys and to other pathogenic 
agents like S. aureus, Burkholderia cenocepacia and Haemophilus influenzae [54–59].  
This model depicts human clinical pathologies such as bacterial persistence and airway 
inflammation [60]. Amongst very recent uses, it successfully evaluated the efficacy of 
liposomal bismuth-ethanediol loaded tobramycin against P. aeruginosa infection in rat  
lungs [61]. Another rat model developed by Pedersen et al., used bacteria embedded in 
seaweed alginate microspheres [62]. Amongst other advances, this model showed the role of 
Psl and Pel polysaccharides as a scaffold of biofilms formed by mucoid P. aeruginosa 
phenotype biofilms in mice [63]. In addition, to study pharmacokinetics/dynamics of colistin 
and imipenem, a neutropenic mouse model of lung biofilm infection was developed [64].  
ii. Intravenous route: Developed by Sawai et al. [65], this model also makes use of pathogens 
embedded in agar beads, which are afterwards injected intravenously to mice. Efficiency of 
several antimicrobials, such as linezolid, quinolones and carbapenems was assessed using 
this model [66,67].  
A relevant infection model of CF should reflect human lung infection characteristics such as airway 
inflammation and spontaneous bacterial infection progressing to chronic stage with characteristic 
biofilm formation. An attempt to achieve this was made in 1992 with a CFTR knock out mouse [68]. 
Though mice did not show spontaneous lung disease, airways inflammation and chronic infection were 
established, and this model was successfully used to model chronic P. aeruginosa lung infections 
using agar beads [69] and to evaluate the efficacy of azithromycin against P. aeruginosa biofilms [70]. 
The CFTR knockout mice provided important information on the molecular mechanisms explaining 
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the efficacy of azithromycin in clinical trials [71]. Recently, this model was also used to mimic lung 
co-infections by P. aeruginosa and B. cenocepacia [72]. CFTR knockouts were later translated into 
pigs (ΔF508/ΔF508) and ferrets. They were used to study S. aureus pathogenesis in CF [73] and 
general CF pathology [74], respectively. 
5.1.2. Other Lung Conditions 
Chronic obstructive pulmonary disease (COPD) related lung infections: COPD is a progressive 
lung disease characterized by emphysema, chronic bronchitis and bronchiectasis. The etiological 
agents of COPD-related airways infection include non-typeable H. influenzae (NTHi), Streptococcus 
pneumoniae, Moraxella catarrhalis and P. aeruginosa [75]. So far, only one mouse model of  
COPD-NTHi lung infection has been reported and allowed to demonstrate the presence of persistent 
multicellular bacterial communities in elastase-damaged lungs and the role of CD54 in NTHi  
clearance [76]. 
Diffuse panbronchiolitis (DPB): DPB is characterized by thickening of bronchiolar walls and is 
commonly associated with accumulation of lymphocytes, plasma cell and histiocytes [77]. There is 
large evidence involving bacterial biofilms in DPB [78,79]. To mimic chronic P. aeruginosa DPB 
infection in the respiratory tract, a murine model was developed in which a small piece of intravenous 
catheter (tube) precoated with P. aeruginosa was inserted into the mouse trachea [80]. This model was 
used to study the efficacy of macrolides against chronic in vivo P. aeruginosa infections and the role of 
inflammatory cytokines and dendritic cells in pathogenesis of DPB [81,82]. 
5.2. Urinary Tract Infection (UTI) 
Urinary tract infections, which include infection of bladder (cystitis) and kidneys (pyelonephritis 
associated with or without kidney stones) primarily affect women and account for nearly 13 million 
annual doctor’s visits in the United States alone [83]. Recurrence of UTI is a major concern with  
20–30% incidences among adult women. However, elderly and prepubertal children are also 
susceptible to recurrent and chronic cystitis [84]. Etiology of UTI is dependent on host genetics, 
biological and behavioral factors and has been largely associated with presence of Escherichia coli  
(E. coli) (80% cases) and to a lesser extent to Staphylococcus saprophyticus (10–15%) followed by 
Klebsiella, Enterobacter, Proteus and Enterococcus species [83,85]. 
5.2.1. Cystitis 
Bacterial colonization of the bladder results in a mucosal inflammatory response called cystitis. 
Uropathogenic E. coli (UPEC) are the most widely studied bacteria [83]. Except for few studies using 
rats where preventive effect of fosfomycin trometamol (FOF) was evaluated against chronic cystitis [86], 
most information on UTI originated from mouse models. In addition to genome availability and 
repertoire of knockout mutants, mice are naturally susceptible to UPEC strains and experimental 
infection closely resembles human disease [83,87,88]. Mouse model of cystitis was efficiently used to 
demonstrate that uropathogenic strains of E. coli and K. pneumoniae exist in biofilm-like large 
aggregates of bacteria (pods or intracellular bacterial communities, IBC) in the bladder epithelial cells 
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suggesting one possible mechanism of recurrent cystitis [89,90]. These pod-like structures were later 
shown to exist in human bladder during UTI [88]. Murine pod like structures exhibited resistance to 
antibiotics and host system [90,91] and were protected against trimethoprim sulfamethoxazole [92]. 
This model has been successfully used to study the molecular mechanisms involved in IBC formation 
and virulence of UPEC such as role two-component system QseBC [93], importance of peptide 
transport, TCA cycle and gluconeogenesis but not glycolysis [94]. Importantly, this model also 
highlighted the role of type 1 pilus and its associated tip adhesin, FimH, in IBC formation. Type 1 
fimbriae were shown to mediate adherence and invasion of urothelial cells [95] via FimH affinity for 
mannosylated urothelium proteins such as uroplakin [95–97]. Consistent with the instrumental role of 
FimH in UPEC bladder colonization, vaccines against FimH as well as FimH specific inhibitors were 
later shown to be protective or efficient against established infection in murine and/or primate models 
of acute cystitis [92,98]. These anti-FimH strategies are very promising and clinical studies proving 
their efficacies are now expected [92,99]. Other prophylactic or curative strategies based on bacterial 
interference and immune system stimulation with non-adherent asymptomatic bacteriuria strain 83972 
were successfully assessed using UTI mouse models and validated in patients [100,101].  
Murine studies have also been extensively carried out to confirm the role of innate immune responses 
in disease outcome and recurrence and highlighted the importance of TLR4 signaling [83,102,103]. 
Furthermore, CD8+ T cells were reported to play a role in adaptive response to UPEC bladder 
infections [104]. Murine UTI model led to identification of biomarkers associated with chronic cystitis 
including elevated serum IL-5 and urine IL-6, G-CSF (Csf2) and KC (CXCL1) [105,106] and more 
recently the autophagy gene Atg16L1 was shown to play an important role in pathogenesis of UTI [107].  
5.2.2. Chronic Bacterial Prostatitis (CBP) 
CBP is a persistent inflammation of the prostrate glands due to bacterial invasion. CBP may account 
for 5–10% of total prostatitis pathology [108]. First evidence of biofilms from biopsied prostatic tissues 
confirmed the presence of sparse microcolonies of S. aureus in the prostatic duct walls [109]. The 
major causative agents are from the Enterobacteriaceae family, like E. coli but also Enterococcus 
faecalis, Pseudomonads, Staphylococcus species and gonococcal organisms [108,110–112]. The 
capacity of these bacteria to form biofilms containing antibiotic persistent bacteria explains recurrent 
CBP [111,113,114]. The rat model has been extensively used to demonstrate the importance of 
virulence factors or quorum sensing systems in CBP [115–117]. This model was also used to evaluate 
therapeutic strategies against E. coli-induced CBP using catechin, ciprofloxacin, or cranberry [118,119] 
as well as the potential of selenium in combination with ciprofloxacin [115]. 
5.2.3. Other UTI 
Infectious urinary stones/calculi or Struvites: Persistent infections caused by urease producing 
bacteria may lead to rapidly growing infectious stones within 4–6 weeks [120,121]. Initial clues of 
biofilm involvement in infectious stones date back to 1971 when Nemoy et al., showed the presence of 
antibiotic resistant bacteria embedded in stone resulted in recurrent urinary infections [122]. The first 
hypothesis that such antibiotic resistance was due to bacteria growing within glycocalyx matrix of 
biofilms [10] was later confirmed by scanning electron microscopy and transmission electron 
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microscopy [123]. The most common urease producers involved in infectious stones are: Proteus spp., 
Ureaplasma spp., Pseudomonas spp., Klebsiella spp., and Staphylococcus species [124]. Moreover, 
Oxalobacter formigenes and Lactobacillus were also suggested to cause nephrolithiasis [125,126]. Rat 
is the most widely utilized animal to develop experimental infectious stones and most of the studies 
were performed with Proteus mirabilis and Ureaplasma urealyticum [127–129]. Using a foreign body 
such as zinc or chalk to develop bladder stones helped understanding the kinetics of stone formation 
and the role of P. mirabilis biofilms in this process [129,130]. This type of infectious urolithiasis rat 
model was also used to study therapeutic strategies against polymicrobial (P. mirabilis, P. aeruginosa 
and E. faecalis) stone infection [128]. 
Pyelonephritis: Once bacteria enter the kidney, they adhere to the urothelium and papillae to form 
biofilm-like structures [131]. While numerous models of acute pyelonephritis have been developed, 
the presence of biofilms was demonstrated solely for P. mirabilis biofilms on the rat urothelium [127]. 
5.3. Digestive Infections 
5.3.1. Intestinal Infections 
The human gastrointestinal tract is covered by a biofilm of commensal bacteria that form 
independent communities depending on the colonized niches [132,133]. Similarly, biofilms were 
shown to colonize the mucus layers of large intestine of other animals such as baboons, rats and  
mice [134,135]. The gut biofilm is shaped by different factors, both environmental and specific to the 
host [136]. Alterations of the flora equilibrium might lead directly to pathology, altered physiological 
and immunological states due to changes in the functional microbial core. Gut diseases can be 
separated in two groups: acute diseases such as diarrhea that are generally due to a pathogenic bacteria 
displacing the commensal flora and impacting directly on intestinal epithelial cells, and chronic 
diseases such as inflammatory bowel disease, commonly named IBD, a group of inflammatory 
conditions of the colon and the small intestine that can evolve to colorectal cancer and that have been 
partly linked with a microbial imbalance of the gut commensal flora (dysbiosis) [137]. The 
streptomycin-treated mouse model of intestinal colonization developed long ago [138,139] has been 
extensively used to study both virulence factors and hosts components involved in intestinal 
colonization (see for example [140]). In addition, infectious colitis models of gnotobiotic mice or 
conventional mice colonized by their natural pathogens such as Citrobacter rodentium have been  
used [141,142]. 
5.3.2. Gall Bladder Infections 
Salmonella enterica serovar Typhi is the causal organism of typhoid fever and is amongst the  
best-studied gut bacteria. Inability of antibiotics to resolve the Salmonella Typhi colonization of the 
gall bladder indicated the role biofilm in this chronic disease [143,144]. A mouse model of chronic 
Salmonella infections was developed by Sukupolvi S et al. [145] and was later used to analyze chronic 
infections that persisted for 1 year following oral infection [146]. Crawford RW et al., (2010) recently 
developed another mouse model of enhanced S. Typhimurium colonization of gall bladder tissue, 
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which allowed visualization through electron microscopy of a dense biofilm covering more than 50% 
of gallstone surface [147].  
5.4. Wounds Infections 
Despite the controversial role of biofilms in delayed wound healing, it is now well accepted that 
wounds are colonized by biofilms as confirmed by SEM and other molecular techniques [148–151]. 
The most commonly studied microorganisms associated with wounds infections are S. aureus and  
P. aeruginosa. Several animal models of traumatic wounds including skin abrasions, burns, lacerations, 
surgical and excisional wounds or open fractures have been published. Dai et al., developed a needle 
scratch mouse model in which they used genetically engineered bioluminescent S. aureus to study 
biofilm formation and the use of photodynamic therapy [152]. Several burn models have been 
developed [150,153], amongst which is a mouse model that allowed the visualization of P. aeruginosa 
biofilms infection in a third degree lesion using PNA-FISH (Figure 3) [154].  
Besides, other animal models were developed to study the involvement of different bacteria, such as 
S. aureus, S. epidermidis, P. aeruginosa and E. coli in excisional wound infections and allowed to  
(i) show the infiltration of inflammatory cells within S. aureus clusters, (ii) confirm the presence of 
“membrane like structures” by electron microscopy (iii) reveal the important role neutrophils play in 
host defense and (iv) assess bacterial susceptibility to antibiotic therapy [156]. In addition, a cutaneous 
porcine wound model allowed the evaluation of topical antimicrobial treatment of S. aureus  
biofilms [157]. In vivo murine models also allowed deciphering the effect of RNAIII-inhibiting peptide 
(RIP, a quorum sensing inhibitor) in combination with teicoplanin against methicillin-resistant  
S. aureus [158] and to directly correlate P. aeruginosa autoinducer with tissue destruction and 
inflammatory response using pressure-induced ischemic wound model in rats [159]. Diabetic patients 
are especially prone to develop problematic wound infections that are colonized by several species of 
microbes forming complex multispecies biofilms of up to 1600 different microorganisms [149,160]. 
Although animal models are scarce, a leptin receptor-deficient mice model was developed to study 
synergistic effects between E. coli, Bacteroides fragilis and Clostridium perfringens in type 2 diabetes 
foot wounds [161].  
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Figure 3. Burn wound infection biofilm in mice model. A. Experimental Settings. Mice are 
subcutaneously anaesthetized, shaved and then covered with a fire blanket and a metal 
plate with a window corresponding to approximately 6% of total body surface. A third-
degree burn is then induced using a hot-air blower for 7 s at 330 °C. Afterwards, mice 
receive fluid replacement and pain therapy during the whole experiment. Lastly, mice are 
infected by alginate embedded Pseudomonas aeruginosa beneath the burn wound 2–4 days 
after burn wound infliction. B. Clinical result 4 days after the procedure. Thermal third 
degree lesion associated with a wound infection. C. Confocal laser scanning microscopy of 
burn wound. A slide of the wound removed in toto is stained with P. aeruginosa specific 
peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) probe (magnification 
× 400). P. aeruginosa forms dense bacterial clusters (black arrowhead) on the surface of 
the burn wound. White arrowhead indicates subcutaneous area. Images Credit: C. Moser, 
K. Thomsen, H. Calum and H. Trøstrup, Department of Clinical Microbiology, Rigshospitalet, 
Denmark. Adapted from [154,155]. 
 
5.5. Endocarditis 
In the early 70s, in order to study infective endocarditis (IE), or the infection of heart inner lining, 
experimental models using rabbits, rats, pigs and cats were developed. However, the fact that 
progression of IE is due to biofilm establishment was demonstrated in the early 2000s [162,163]. 
Although, several microorganims have been associated with IE, including streptococci, staphylococci, 
and Candida [164,165], S. aureus is the major cause of endocarditis and thus, has been extensively 
studied in experimental IE. Rabbit endocarditis model has been used to decipher genetics of S. aureus 
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biofilms in vivo, for instance, the positive modulation of the alpha-toxin gene (hla) by agr, sarA and 
sae, three major S. aureus global regulators [166]. In addition, the rabbit model allowed the study of 
streptococcal endocarditis confirming the presence of a biofilm structure by electron microscopy 
(Figure 4) [167,168]. A rat model of IE was also developed wherein endocarditis was induced by 
continuous low-grade bacteremia mimicking spontaneous bacteremia in humans [169]. This model 
was later used to highlight the role of S. aureus adhesion to fibrinogen and fibronectin, as well as 
platelet aggregation, in the initiation of in vivo IE [170]. Several other animal studies have been 
performed to evaluate the efficiency of single or combination therapies against IE with oritavancin, 
vancomycin, gentamicin, daptomycin or ceftobiprole [171–173]. 
Figure 4. Native valve endocarditis in rabbit model. A. Post-mortem examination of a 
rabbit heart. Aortic endocarditis is induced in female New Zealand White rabbits by 
insertion of a polyethylene catheter (black arrow) through the right carotid artery into the 
left ventricle. Twenty-four hours after catheter insertion, pathogenic bacteria were inoculated 
through ear vein in each rabbit. The catheter is left in place throughout the experiment. 
Animals are killed 8 h after the last antibiotic injection and the vegetations (white 
arrowheads) from each rabbit are excised, rinsed in saline, pooled, and weighed. White 
arrow: left ventricle wall; black arrowhead: aorta; black star: aortic valve. B. Scanning 
electron microscopy of vegetation after 11 days of infection. Biofilm formed by 
Streptococcus spp. at the surface of native aortic valve. C. Transmission electron microscopy 
of bacteria from vegetation after 11 days of infection. Ruthenium red staining reveals the 
presence of an extracellular matrix (black arrowhead) surrounding Streptococcus spp. 
(white arrowhead) causing native aortic endocarditis. Images credit: A.-C. Crémieux 
(EA3647, Université Versailles Saint-Quentin), V. Dubée and B. Fantin (EA3964, 
Université Paris Diderot, Faculté de Médecine, Paris, France). Adapted from [167,168]. 
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5.6. Ear, Nose, Throat Infections 
5.6.1. Chronic Otitis Media (OM) 
OM is the infection of middle ear leading to inflammation and is one of the most common diseases 
affecting children. First evidence of biofilm involvement was confirmed by direct detection in mucosa 
samples recovered from middle ears of children with chronic and recurrent OM [174]. Three major 
pathogenic agents of OM, S. pneumoniae, nontypeable H. influenzae (NTHI) and M. catarrhalis 
formed biofilms in vivo [175]. The most commonly used models for OM are chinchilla, mouse and  
rats [176–178]. The first chinchilla model was developed in 1976 using S. pneumoniae and was later 
used to study pathogenesis, immune response, efficacy of antimicrobials against S. pneumoniae and 
vaccine candidates [179–181]. Chinchilla has several advantages such as long life span of 15 years, 
strong ear anatomical similarity to humans, intact organ systems and immune functions, presence of 
large cephaloid bulla that make sampling easier and sufficient [176,182]. Moreover, this model enables 
direct visualization of biofilm development on the middle ear mucosa by CLSM [183,184]. Amongst 
other reports, this model showed that group A streptococcus (GAS) biofilms are inhibited in absence 
of virulence regulator Srv [185] and that c-di-GMP improves persistence of P. aeruginosa biofilms in 
chronic supportive OM [186]. 
Murine models of OM have also contributed to better understanding virulence factors, bacterial 
adhesion, invasion mechanisms, and general or specific inflammatory responses [178,187]. For 
instance, the use of Swiss-webster mice highlighted the role of pneumococcal proteins PavA, UspA or 
(Usp) A2 in adhesion [188,189].  
In order to study long-term chronic OM, several models were adapted, for example, the primate 
model in cyanomolgus macaques to study the P. aeruginosa biofilms [190], a rat model that allowed 
follow up of S. pneumoniae up to 7 months [191] or plasminogen (plg)-deficient mice to study 
spontaneous development of chronic OM with varying inflammatory responses over a period of  
18 weeks [192]. 
5.6.2. Chronic Rhinosinusitis (CRS) 
Chronic rhinosinusitis is the inflammation of paranasal sinuses, mainly due to bacterial invasion, 
typically of S. aureus, CoNS (coagulase negative staphylococci), P. aeruginosa, S. pneumoniae or  
H. influenzae. Several clinical studies demonstrated biofilm morphology in mucous samples from 
human CRS [193,194]. The most common CRS model is rabbit which allows animals monitoring up  
to 9 months for signs of inflammation [195,196] but mouse and sheep models have also been  
developed [197–199]. 
5.7. Dental Biofilms 
Dental plaque is one of the most common types of polymicrobial biofilms that develop on 
susceptible tooth surfaces [200–202].  
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5.7.1. Dental Caries 
The main factors governing the virulence of the dental caries pathogenicity are extracellular 
polysaccharide (EPS) matrix and acidified plaque milieu [203]. Several models have been developed 
to study the cariogenic biofilms, amongst which, the most widely used is the rodent model of 
cariogenesis using streptococci. It has enabled us to define the infectious character of the disease, role 
of different genes in cariogenic process and the effect of salivary proteins in plaque formation [204–
206]. Topical administration of bacteria to study dental plaques has been carried out in Sprague 
Dawley rats and there is evidence of different outcomes in host response depending on genetic 
background of rats [207,208]. Furthermore, this model has been used to evaluate antimicrobials against 
dental plaques [209,210]. 
5.7.2. Periodontitis 
Periodontitis, or destruction of periodontium structure, is due to the presence of pathogenic biofilms 
on the gingival and periodontal tissues resulting in heightened inflammatory response. It involves both 
innate and acquired immunity [211,212]. The major pathogens causing supra and subgingival biofilms 
are Gram-negative anaerobes such as Porphyromonas gingivalis, Treponema denticola and Tannerella 
forsythia, referred to in humans as “red complex” [213]. Many models of periodontitis have been 
developed using primates, dogs, rodents, rabbits, pigs and ferrets [214,215]. Nevertheless, the use of 
superior mammals has ethical, handling, housing and expense related issues [216–218]. Thus, their use 
should be confined to preclinical studies. Rodents have dental gingival area similar to humans [219], and 
periodontitis disease was also shown to induce bone loss in these animals [220,221]. Hence,  
use of rodents is relevant to study microbiological and immunological aspects associated with 
periodontitis [212,222]. For example, it has been shown that T. denticola persisted in a mice gavage 
model up to 71 days and significantly reduced IL10 [223] whereas P. gingivalis could be detected up 
to 11 weeks with migration of monocytes and neutrophils in gingival connective tissues [207]. Several 
studies in rodents have also addressed synergistic effects of such polymicrobial infections in 
periodontitis outcome [200,222,224]. Finally, an experimental rabbit model was used to evaluate 
efficiency of different anti-inflammatory molecules and antimicrobials such as resolvins, protectins, 
lipoxins in periodontitis induced by P. gingivalis [225]. 
5.8. Other Biofilm-Related Infections 
5.8.1. Osteomyelitis 
Osteomyelitis, or the infection of the bones or bone marrow, is a frequent complication associated 
with open fractures [226]. Direct scanning electron microscopy confirmed the presence of bacterial 
biofilms in osteomyelitic bone samples [227,228]. Since the first study in 1941 of S. aureus chronic 
osteomyelitis in tibia [229], the rabbit model has been widely used to study chronic bone infection. 
This has allowed to identify proteins involved in S. aureus biofilm development in bones, and to 
evaluate the effect of various antimicrobials [230–232]. In another study, an experimental rat model of 
MRSA osteomyelitis was used to demonstrate the superiority of fosfomycin over daptomycin in 
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treating osteomyelitis [233]. More recently, a non-invasive mouse model using bioluminescence 
allowed monitoring of chronic femur S. aureus infection up to 21 days [234]. 
6. In vivo Models of Device-Related Infections 
The first evidence of the involvement of biofilm in device-related infections was provided in 1982 
with electron microscopy study of a pacemaker implanted in a patient with recurrent S. aureus 
bloodstream infection [235]. Since then, almost all types of indwelling devices have been associated 
with the occurrence of bacterial or fungal biofilms (Figure 1) [162]. Because of a high tolerance 
towards antibiotics, these device-related infections are difficult to treat and expose patients to the risk 
of recurrence [236]. As the role of biofilm has been increasingly recognized, many in vivo models of 
device-related infections have been developed to validate in vitro data regarding mechanistic 
questions, as well as to assess the preventive or curative approaches specifically targeting biofilm 
lifestyles [237–240] (Table 3).  
In vivo models of device-related infections can be broadly divided in two groups. On the one hand, 
the foreign-body is inserted in the organ or in the same position as it is used in clinics. Examples of 
these “site-specific models” are intravascular catheter models or intrafemoral pins or wires. On the 
other hand, the foreign-body is inserted in a subcutaneous pocket so that there is no contact with a 
specific structure or organ, therefore defining the “subcutaneous models” such as tissue cage model or 
subcutaneously inserted pieces of catheters. 
6.1. Site-Specific Models 
6.1.1. Vascular Catheters 
During an outbreak of catheter-related infections, the observation that S. epidermidis was able to 
produce extracellular matrix (in the past called “slime”) and adhere to surfaces identified the importance 
of biofilm in this setting [241,242]. First attempts to set-up in vivo models relied on the subcutaneous 
implantation of catheter cut in pieces (see the “subcutaneous models” section) [237]. Even though this 
approach helped understanding mechanisms involved in S. epidermidis biofilm formation, these 
models lacked several important features of catheter-related infections such as interaction with blood 
components or blood flow [243]. These limitations led to considerable efforts to develop in vivo 
models integrating these aspects. 
The most popular intravascular venous catheter model developed to study bacterial colonization and 
subsequent infection was described in 1999 using a silastic catheter inserted into the superior vena 
cava of adult rats [239]. The rat model has been used to validate the in vivo importance of 
polysaccharide intercellular adhesin (PIA) and autolysin AtlE in the establishment of a S. epidermidis 
biofilm and in its pathogenesis (bloodstream infection and metastatic disease) [239,244]. This model 
allowed assessing preventive approaches, such as use of RNAIII-inhibiting peptide (RIP) [245] or 
vaccination with immunization of rats prior to catheter insertion leading to a protective effect towards 
bacterial colonization of the device by S. aureus or S. epidermidis [246]. Other animals such as rabbits 
or mice have also been used to develop such central venous catheter (CVC) models with similar 
surgical procedures [247,248]. 
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Figure 5. Totally implantable venous access port (TIVAP)-associated biofilm using rat 
model. A. Experimental Settings. Rats are anesthetized and shaved before starting the 
procedure. After skin disinfection, an incision is made at the dorsal midline, a 
subcutaneous pocket is created and the port is carefully inserted before being held intact by 
sutures. An incision is made in the neck area on the ventral side in order to access the 
external jugular vein. The catheter is inserted into the vein and pushed up to the superior 
vena cava. Suturing of both the dorsal and ventral sides closed the wounds and rats 
received analgesia at the end of the experiment. B. Monitoring of TIVAP colonization by 
E. coli. Five days after TIVAP insertion, 10
4 
CFU of E. coli in 100 µL are injected into the 
port and photon emission is measured over a period of 10 days to monitor biofilm growth. 
Dorsal view of a representative rat, showing progression of biofilm signals towards the 
catheter tip and then restriction to the port. C, D, E and F. Bacterial colonization of TIVAP 
leads to biofilm formation. Rats are sacrificed 10 days post-infection and TIVAP are 
removed aseptically for examination. C. Photon emission of the removed TIVAP colonized 
by E. coli biofilm. D. Macroscopic examination after septum removal showing blood clots 
and deposits inside the port. E. Bacterial cells are harvested from the catheter and port 
separately and plated on LB agar for CFU counting. F. SEM images confirming biofilm 
formation in TIVAP in vivo in the port and catheter. Adapted from [256]. 
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Attempts to eradicate in vivo biofilms have been made using antibiotic lock technique/therapy 
(ALT). In this treatment, a highly concentrated antibiotic solution is allowed to dwell for 12 to  
24 hours inside the lumen of a catheter. Conclusions of the different studies are difficult to compare as 
different authors used various compounds, concentrations and time of treatment. It was demonstrated 
that against S. aureus, quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin dwelling for 
1 hour were able to reduce the amount of survival CFU in blood and on catheter tip but none of them 
eradicated biofilm, suggesting the importance of a longer dwelling time [249]. ALT composed of 
daptomycin associated with systemic treatment was also assessed in order to eradicate S. aureus and S. 
epidermidis catheter-related infections using polyurethane CVC: vancomycin and daptomycin were 
equally efficient against methicillin-resistant S. epidermidis (MRSE) infection [250]. A rabbit CVC 
model allowed researchers to demonstrate that heparin had no effect and that it did not improve the 
efficacy of vancomycin or ciprofloxacin ALT on S. aureus biofilm [251]. Later, the same group 
compared linezolid, vancomycin, gentamicin and ciprofloxacin antibiotic solutions as ALT against S. 
aureus biofilm. In this model, gentamicin (40 mg/mL) was the most efficient drug against methicillin-
susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) [252]. In addition, association 
of minocycline-EDTA as lock therapy has been shown to efficiently reduce the number of rabbits with 
positive blood cultures and in eradicating biofilm on the catheter tip [253]. All these data have been 
used to design clinical studies and some of these compounds are now used in clinics [254,255]. 
Recently, we developed an in vivo model of totally implantable venous access port (TIVAP)-related 
infection to study long-term biofilms (Figure 5) [256]. TIVAPs are used for antineoplastic chemotherapy, 
parenteral nutrition or blood products in humans. These devices are composed of a vascular catheter 
inserted into the external jugular vein of a rat connected to subcutaneous port. This model does not 
require the use of a restraint jacket and use of bioluminescent strains allows long-term non-invasive 
monitoring of biofilm formation. We used this model to demonstrate the ability of an association of 
gentamicin and tetrasodium EDTA to eradicate 3-day old biofilm of S. epidermidis, S. aureus (MRSA 
or MSSA), P. aeruginosa and E. coli [257]. A clinical study can now be set-up, based on these data. 
6.1.2. Urinary Catheters 
The observation that systemic antibiotic failed to eradicate bacteriuria without removal of the 
urinary tract device was made decades ago [258]. In 1985, the electron microscopic study of a urethral 
catheter removed due to relapsing catheter associated urinary tract infection (CAUTI) revealed the 
presence of a bacterial biofilm [259]. Since then, many in vivo models have been developed in order to 
mimic these situations. Most of them rely on the insertion of a foreign-body inside the bladder and 
may or may not include a surgical procedure. Therefore, urinary catheter-associated models can be 
classified in 3 groups: (i) and (ii) foreign-body left inside the bladder with or without a surgical 
procedure; (iii) a complete urinary catheter with a tip located inside the bladder, associated with a urine 
collection system and exiting through urethra. 
(i) Surgical models. These models rely on the surgical insertion of a foreign-body inside an animal 
bladder such as glass beads [260] or pieces of urinary catheter [261]. They allowed the study the effect 
of persistent bladder colonization on renal scaring [260] but also to assess different therapeutic 
strategies [260,261]. First develop in rats, the same model was later adapted in mice to demonstrate the 
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use of mannitol as an adjuvant to gentamicin to eradicate biofilm persisters of E. coli, which can be a 
promising clinical candidate [262]. 
(ii) Non-surgical models. The principle of these models is to transurethrally insert pieces of catheter 
inside the animal bladder [263]. These models have been developed in rats, rabbits and mice to study 
several aspects of CAUTI such as bladder inflammation [263], virulence of E. faecalis on a silicone 
implant [264] or preventive approaches such as Triclosan
®
 (a broad spectrum antiseptic) [265]. 
Various curative treatments have been assessed in these models, such as antibiotics alone [266] or in 
the association with small molecules (like mannosides) to prevent CAUTI [267]. This adjuvant 
approach still needs to be validated in clinic. 
(iii) Models of externalized urinary catheters. In order to mimic a complete urinary catheter with an 
externalized system, urethral models were developed in rabbits and sheep and used to study the effect 
of systemic antibiotics on viable cell count or biofilm structure on the catheter tip [268,269]. 
Preventive approaches have also been assessed such as antiseptic-coated catheters like Gendine [270] 
or Low-Energy Surface Acoustic Waves [271]. Another approach was developed using a sheep model 
to study iontophoresis as a preventive measure [272]. In this model, urethral catheters are modified in 
order to deliver a current to electrodes located on the catheter tip leading to the production of ions of 
soluble salts and allowing the formation of local biocide. After 20 to 21 days, this approach 
significantly reduced bacterial burden in urine.  
Even though all these models identified promising compounds, clinical studies remain rare or gave 
negative results such as a recent clinical study using antibiotic-coated catheters without any significant 
clinical benefit [273].  
6.1.3. Orthopedic Implants and Prosthetic Joints 
First reported work trying to reproduce osteomyelitis in rabbits was published as early as  
1885 [274]. In early 70’s, it was shown that the presence of a foreign-body inserted into a rabbit tibia 
(stainless steel pin) could potentiate the development of chronic S. aureus osteomyelitis [275]. 
Interestingly, it is only ten years later that the link between biofilm formation and orthopedic devices 
was confirmed in clinics and using a rabbit model of foreign-body inserted inside the tibia [276,277]. 
Even though rabbits have been frequently used for these studies, orthopedic implant models have been 
developed in many other animals with a wide range of foreign-bodies and sites of insertion (see Table 3). 
These models allowed the study of the influence of various types of materials such as stainless steel, 
titanium, cobalt chromium, polyethylene or polymethylmetacrylate on bacterial adhesion [278,279]. It 
has also been demonstrated that bone devascularization, presence of foreign-body and bacterial 
virulence played a key role in the incidence of osteomyelitis [280]. Moreover, the impact of adaptive 
immune responses was studied to show that Th2/Treg responses played a key protective role against 
chronic S. aureus implant infection [281]. Besides, preventive approaches have been assessed, such as 
use of gentamicin for systemic and local treatment or as a coating of the device [282,283]. Lastly, 
different models have been developed to study antibiotic-impregnated cement or implants [284]. 
Promising results were obtained using gentamicin-coated nails in the tibia in a clinical pilot  
study [285]. 
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Even though osteomyelitis and prosthetic joint infections (PJI) share common features, different 
animal models have been developed in order to assess specific characteristics of PJI. These models 
allowed to study diagnostic procedures such as magnetic resonance imaging (MRI) modification after 
S. aureus PJI [286] as well as preventive approaches like gentamicin-loaded bone cement for 
prevention of E. coli PJI [287] or prevention of S. aureus PJI after bloodstream infection [288]. 
Another preventive approach relying on a minocycline/rifampin-impregnated bioresorbable  
polymer implant coating has been shown to reduce biofilm formation [289]. Another key contribution 
of these models is the study of distribution and efficacy of frequently used antibiotics such as 
fluoroquinolones [290].  
6.1.4. Endotracheal Tubes 
Biofilm formation in endotracheal tubes was described in 1989 [291] and it is now considered that 
they can constitute a potential source of ventilator-associated pneumonia (VAP) that can escape 
antibiotics in case of systemic treatment [292]. Animal models using sheep, pigs or dogs have  
been developed. They rely on the orotracheal intubation of animals with endotracheal tubes and 
mechanical ventilation for 24 to 96 hours and have been used to study preventive or curative strategies  
(see Figure 6) [293–295]. These models have, for example, been used to demonstrate the effectiveness 
of endotracheal tubes coated with silver-sulfadiazine/chlorhexidine in polyurethane or silver hydrogel 
coating to reduce bacterial colonization [293,295]. These data enabled the performance of a clinical 
study demonstrating that this approach significantly reduced the incidence of VAP in clinics [296]. 
This model was later used to show that a mechanical removal of biofilm from the surface of 
endotracheal tubes prolonged the bactericidal activity of such coated devices. This approach called 
“mucus shaver” allows the retention of the device in place and biofilm removal from its surface [297]. 
This mucus shaver procedure was assessed in a pilot study including 12 patients in each group and 
allowed a significant reduction of the number of endotracheal tubes colonized with biofilm [298].  
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Figure 6. Model of endotracheal tube biofilm–associated infections in ventilated pigs.  
A. Experimental Settings. Large-White Landrace female pig (36 Kg) orotracheally intubated 
and mechanically ventilated. Following intubation, the animal received an oropharyngeal 
challenge of Pseudomonas aeruginosa. During mechanical ventilation, endogenous 
oropharyngeal bacteria and Pseudomonas aeruginosa rapidly colonize the internal surface 
of the endotracheal tube. Bacteria within the endotracheal tube constitute a persistent 
source of pathogens, which may result in ventilator-associated tracheobronchitis and 
pneumonia. B. Endotracheal tube internal surface following 72 hours of mechanical 
ventilation. After extubation, the endotracheal tube external surface is cleaned with sterile 
gauzes and decontaminated by careful rinsing with 80% alcohol and saline solution and 
then longitudinally sliced open. Two 1 cm long sections and one 3 cm long section of the 
dependent half of endotracheal tube are dissected for confocal electron microscopy, scanning 
electron microscopy and quantitative microbiological studies, respectively. C. Scanning 
electron microscopy (magnification × 2000) of the internal surface of endotracheal tube 
(lateral view). Bacterial communities are adherent to the endotracheal tube surface and 
surrounded by the extracellular matrix. D. Confocal laser scanning microscopy of the 
internal surface of endotracheal tube (lateral view). The lumen of endotracheal tube is 
stained with BacLight Live/Dead stain (magnification × 250). Pseudomonas aeruginosa 
biofilm is adherent on the internal surface of endotracheal tube. Eukaryotic cells are also 
present within the biomass. Images Credit: G. Li Bassi and L. Fernandez-Barat, Pulmonary 
and Critical Care Unit, Division of Animal Experimentation, Hospital Clinic, Barcelona. 
Adapted from [294,299]. 
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6.1.5. Vascular Grafts 
Identification of involvement of biofilm in the occurrence of vascular graft-related infection was 
made at the end of the 80’s [300]. Such graft-related infection was later studied in a dog model to 
develop diagnostic or surgical procedures [300]. This model relied on the implantation of dacron 
prosthesis colonized by S. epidermidis on the infrarenal aorta of a dog leading to the development of a 
prosthetic vascular graft infection (PVGI). This model was notably used to study the effectiveness of 
rifampicin-bonded gelatin-impregnated grafts in reducing the number of animals with persistent 
biofilm colonization [301]. Another group confirmed that rifampicin-soaked silver-coated polyester 
(RSSCP) was more efficient than expanded polytetrafluoroethylene (ePTFE) graft replacements, in the 
treatment of aortic PVGI porcine model [302]. This model was also adapted in miniature pigs to 
demonstrate that Dacron graft bonded with chlorhexidine, rifampicin, and minocycline was a good 
candidate for the prevention of S. aureus related infections [303]. First clinical studies using  
antibiotic-impregnated grafts gave promising results in humans but still need to be confirmed by 
comparative trials [304]. 
6.1.6. Tissue Fillers  
In 1992, study of removed silicone devices, such as mammary implants or tissue expanders led to 
the identification of bacterial biofilm on the surface of these foreign-bodies [305]. The development of 
biofilms was associated with the occurrence of capsular contraction, a late complication of such 
foreign-bodies. A porcine model has been used to study biofilm formation on the surface of breast 
implants [306,307]. Implants were inserted with or without a circular disk of minocycline-rifampicin-
impregnated polypropylene mesh and left in place for 16 weeks [306]. This preventive approach 
reduced the incidence of capsular contracture and biofilm formation.  
6.1.7. Contact Lenses 
Identification of contact lens as a suitable surface for bacterial adhesion and biofilm formation was 
made at the end of 80s [308]. Biofilm colonization has also been demonstrated to be associated with 
the occurrence of corneal ulceration [309]. Several animal models have been developed to study 
contact lenses tolerance or the influence of bacterial inoculation on the incidence of keratitis such as 
rabbit model or guinea pig model [310]. While these models have never been used to specifically 
address questions regarding bacterial biofilms, a specific mouse model has been developed in 2010 in 
order to study fungal biofilms on contact lenses and its link to keratitis [311]. 
6.1.8. Dental Implants  
Confocal laser scanning microscopic studies of oral implants confirmed that biofilm was present 
with a structure close to what is seen in dental plaque [312]. It has also been shown that the 
development of these dental implant-related biofilms could play a role in periimplant infections (also 
called periimplantitis) and progressive bone loss around the implant. The first animal model of dental 
implant-associated infections was developed in 1992 involving the replacement of mandibular  
right premolars by complete titanium implants [313]. In this model, mucosal lesions around  
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implant-associated plaque or teeth-associated plaque were comparable but bacterial biofilm per se has 
not been studied [314]. However, a rat model has been developed to specifically study the effect of 
Aggregatibacter actinomycetemcomitans biofilm [315]. 
Aside from these animal models, different groups developed human models. All these human 
models rely on the positioning of a fixation system applied on the mandibular region, inside the mouth 
of healthy volunteers on which disks made of various surfaces can be placed. For instance, this 
approach has been used to study the impact of surface roughness on plaque colonization of titanium 
device [316]. Another group used this approach to demonstrate that bacterial adhesion on implant 
surfaces was significantly lower with zirconium oxide surface as compared with pure titanium [317].  
6.2. Subcutaneous Foreign-Body Models 
6.2.1. Tissue Cage 
These models were developed in the early 80’s to mimic a foreign-body-related infection [240]. 
These cages consist in rigid tubes with perforations and sealed at each end. These devices can be 
implanted in mice, rats, hamsters, guinea pigs [240] and ponies. Bacterial contamination can be made 
before or after tissue cage insertion by a percutaneous injection inside the tissue cage. This model has 
been used to study different aspects ranging from the influence of host immune response to the 
effectiveness of different treatments [318]. For instance, the efficacy of adjunction of rifampicin in 
treatment regimen was suggested in tissue cage models before being confirmed in clinical studies [319]. 
Fosfomycin and daptomycin are currently being investigated and could be promising candidates 
against foreign-body-related infections [318]. For an extensive review of these models, see [22,320]. 
6.2.2. Vascular Catheters  
This model has mostly been developed using mice and involves the insertion of a 1-cm segment of 
vascular catheter under the skin, in a subcutaneous space [243]. The biomaterial can be contaminated 
by bacteria before or after the surgical procedure and various biomaterials have been used including 
Teflon
®
, polyurethane, silastic, latex, dacron, Gortex
®
 [243]. This model was, for example, used to 
study the importance of staphylococcal accessory regulator (sarA) and ica for S. aureus in vivo biofilm 
formation [321]. Another group recently demonstrated that there was a reduction in cytokine production 
during biofilm formation and limited macrophage invasion into S. aureus biofilms in vivo [322]. This 
model can be used to assess therapeutic options in order to mimic ALT with the injection of antibiotic 
inside the lumen of subcutaneous catheters [323]. Preventive approaches can also be assessed like the 
use of cerium nitrate, chitosan and hamamelitannin to prevent the formation of biofilm of S. 
epidermidis, S. aureus, Acinetobacter baumannii or C. albicans [324]. Many authors use bioluminescent 
variants of bacteria to follow colonization non-invasively [325]. Using a rabbit model of subcutaneous 
catheters, minocycline and rifampin coating prevented the colonization by S. aureus [326], which later 
was demonstrated to be more efficient than chlorhexidine+silver sulfadiazine coated vascular catheters 
in a human clinical trial [327]. Other vascular catheter coatings have been studied such as triclosan and 
dispersin B (an antibiofilm enzyme) to prevent S. aureus colonization [328].  
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6.2.3. Other Subcutaneous Models 
Bone cement. A study comparing two commercial acrylic bone cements shaped like a disk 
demonstrated that association of gentamicin-loaded cement and pulsed ultrasound reduced by 50% the 
number of viable bacteria recovered from the surface of the implant after sacrifice [329]. 
Pacing device. A rabbit model has been developed to study biofilm formation on the surface of a 
pacing device, which demonstrated that the use of a mesh envelope incorporating minocycline and 
rifampicin around the device prevented biofilm formation of S. epidermidis, S. capitis, E. coli and  
A. baumannii [330]. 
Cardiac valves. To study cardiac valve-related infections, in vivo models were developed in guinea 
pigs [331], mice [332] and rabbits [333]. This type of studies focused on the use of silver-coated 
polyester fabric [331] or minocycline/rifampin coated sewing cuffs to prevent bacterial colonization 
and infection [334]. 
Vascular grafts. Different models were developed in hamster [335], mice and rats [336]. These 
models have been used to study preventive approaches such as antibiotic bonded grafts or vancomycin 
delivered from glycerylmonostearate (GMS) implants [336]. Different curative approaches have been 
studied using these models including intraabscess urokinase associated with systemic gentamicin [335] 
or quorum-sensing inhibitor FS3-coated vascular graft associated with daptomycin [337]. 
Polyethylene disks. Subcutaneous implantation of polyethylene disks in mice or rabbits showed 
promising effects of ultrasound combined with systemic gentamicin against E. coli [338].  
Beads. Polymethylmethacrylate beads loaded with or without the quorum-sensing inhibitor RIP 
associated with or without vancomycin were inserted in subcutaneous space of rats. This approach 
efficiently prevented S. aureus biofilm formation [339].  
Surgical meshes. This model involves the insertion of resorbable or non resorbable surgical meshes 
colonized by S. aureus biofilm inside subcutaneous pockets [340]. While biofilm persisted around  
non-degradable meshes up to 28 days, bacteria disappeared from surrounding tissues in case of 
degradable mesh [341].  
7. Take-Home Messages and Future Directions 
7.1. Pitfalls of in vivo Biofilm-Related Infection Models 
As discussed in this review, use of numerous in vitro and in vivo models in the last twenty years has 
provided massive information on most human biofilm-related infections, even though models 
dedicated to some biofilm-related infections are missing (see Table 4). Numerous in vivo models have 
been developed for each infectious disease to address specific questions regarding initial adhesion, 
assessment of different surfaces, preventive or curative approaches, as illustrated by the large number 
of models used to study CVC-related infections [243,248,256]. Therefore, there is no “gold-standard” 
as each model may provide an answer to a specific question, depending on host immune system, size 
or surface of the device and environment. These multiple models provide researchers with a myriad of 
options in order to choose the more appropriate model that will answer the biological question raised. 
However, a concerted effort is needed to standardize studies using identical models (in term of animal 
lineages, route and dose of inoculation, etc.) so that scientists using the same model can compare their 
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results. For instance, among studies dealing with ALT for CVC-related infections, several drugs were 
studied at different concentrations or dwelling times, therefore, impeding any comparisons between 
results [249,251,252]. In other fields, scientists have proposed guidelines to standardize assays and 
their interpretation in order to homogenize their results (see for instance [342]). Such an effort should 
be made in in vivo modeling of biofilm-related infections. 
Table 4. Biofilm-related infections without specific in vivo model. Among them, some 
diseases have in vivo models but without any application for biofilm studies. 
Type of biofilm-related infection Animal model for the disease (References) Implication of biofilms in clinics (References) 
Tissue-related infections   
Keratitis Yes [446] Yes [447] 
Endophthalmitis Yes [448] Yes [449] 
Chronic tonsillitis Yes [450] Yes [451] 
Chronic laryngitis No Yes [452] 
Bacterial Vaginosis Yes [453] Yes, reviewed [454] 
Meningitidis Yes [455] Yes, discussed and reviewed in [456] 
Device related-infections   
Cochlear implants No Yes [457] 
Voice prosthesis No Yes [458] 
Neurological devices No Yes, reviewed in [459] 
Penile prosthesis No Yes, reviewed in [460] 
Biliary stent Yes [461] Yes [462] 
Furthermore, many concerns have been raised regarding the scarce translation from in vitro and  
in vivo models to clinical studies [343]. This drawback is not limited to the field of microbiology but 
probably reflects limitations of in vivo studies [344]. First, obviously, differences exist between 
humans and animals used for in vivo studies, especially response towards microorganisms or their 
components. A striking example of the latter is the difference between human and murine sensitivity to 
LPS that may distort conclusions of studies relying only on this model [345]. Secondly, the choice of 
animal for in vivo studies is frequently based on experimental convenience and rarely include 
environmental factors that have been shown to have important influence on the outcome of an  
infection [346]. The same can be argued for the choice of bacterial strains that may not be representative 
of the natural setting. One well-known example is the use of non-mucoid PAO1 P. aeruginosa 
laboratory strain that causes acute types of infection, which are not representative of the clinical 
symptoms in CF chronic infection. Lastly, as for other in vivo studies, rigorous statistical analysis and 
experimental set-up are mandatory in order to avoid any false positive interpretation [347]. One can 
foresee that recent publication of new guidelines for reporting animal research will improve quality of 
experimental in vivo models [346,348]. 
7.2. Under-Developed Aspects of Biofilm-Related Infections 
7.2.1. Synergy between Biofilm Tolerance and Resistance Genes and Their Impact on Nosocomial 
Infections 
One major challenge of biofilm research is to understand and tackle the increased tolerance of 
biofilms towards antimicrobial agents including antibiotics [236]. This ability to endure high concentration 
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of antibiotics complicates treatment of biofilm-related infections and is a threat that is enhanced  
by microorganisms carrying resistance genes such as extended spectrum β-lactamase (ESBL) or 
methicillin-resistance. Increased frequency of horizontal transfers such as conjugation, transformation 
or transduction has been demonstrated in vitro within biofilms [349]. Hence, biofilms may also be 
expected to facilitate the transfer of resistance genes as demonstrated in an in vitro study with an 
increased rate of transfer of a plasmid encoding CTX-M-15 (an ESBL) in a K. pneumoniae biofilm as 
compared to planktonic conditions [350]. Interestingly, many transmissible DNA elements encode 
biofilm promoting factors including various adhesins such as conjugative pili, fimbriae or autotransporter 
adhesins and persistence genes such as toxin/anti-toxin modules. This, therefore somehow promotes 
their own transfer by means of their capacity to increase biofilm formation or antibiotic tolerance. 
Additionally, these phenomenon may be favored by architecture of biofilms in which antibiotics reach 
certain areas of biofilms only at sub-inhibitory concentrations that are known to increase (i) the 
likelihood of selecting resistant mutants; (ii) rate of mutations; (iii) biofilm formation and (iv) gene 
transfer [351–353]. 
The possible interplay between biofilm tolerance, gene transfer and spread of resistance can be of 
key-importance in nosocomial settings but remains to be demonstrated in clinical settings or even in a 
relevant in vivo model of biofilm-related infections. Therefore, establishing in vivo models allowing 
the study of mechanisms developed by biofilm bacteria to survive antibiotics is a major challenge that 
should be met in the coming years. 
7.2.2. A Switch towards Models to Study Biofilm Polymicrobial Infections? 
While environmental biofilms are known to be composed of multiple species, the concept and 
demonstration that human infections can arise in the context of polymicrobial biofilms has been 
overlooked until recently. Koch’s postulates associating one microorganism with one disease as well 
as the extensive use of culture-dependent isolation techniques have for long time masked the possibility 
that the nature of the flora among which the pathogenic bacteria are embedded can strongly influence 
its behavior and the infection outcome. Today, due to the advent of culture-independent methodologies, 
many tissue infectious diseases are likely associated with the presence of multiple microorganisms like 
otitis media, oral cavity diseases, vaginosis, wound infections and CF lung infections [354]. The 
formal demonstration of the existence of polymicrobial biofilms and their link to infection is still a 
matter of debate (see the reviews [354,355]). Nevertheless, several studies allowed direct visualization 
of polymicrobial biofilms in patients. For instance, electron microscopy studies of biofilm in chronic 
wounds demonstrated the presence of biofilm composed of bacteria of various morphotypes (rods and 
cocci) [149]. This diversity was confirmed using molecular biology tools. Specific FISH probes were 
also used to show that some biofilms in chronic otitis media are composed of H. influenzae and  
S. pneumoniae [174]. Interestingly, analyses of the flora comprising biofilms responsible for catheter 
associated infections like CAUTI or catheter-related bloodstream infections (CRBSI) also demonstrated 
the presence of multiple species [356,357]. It is therefore suspected that a large part of biofilm-related 
infections might be indeed linked to the presence of polymicrobial biofilms. Until now, several  
well-suited in vitro models to characterize interactions between species have been developed 
especially using microorganisms colonizing the oral cavity, the intestine or wound infections (see, for 
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example [25,358,359]). Surrogate non-mammalian animal models are also used to study such 
polymicrobial interactions within biofilms. For instance, the behavior of P. aeruginosa in presence of 
other bacteria such as S. aureus and that of A. actinomycetemcomitans in presence of S. gordonii was 
analyzed using D. melanogaster [359,360]. While relatively few, several studies of polymicrobial 
infections using in vivo mammalian models have been conducted recently using otitis media, wound, 
UTI or CF lung models [72,360–363]. Although these studies were performed with different models 
and microorganisms, they showed that the colonization, infection and host response was totally 
different depending on single or multiple species infections with notably an increased ability to 
colonize or cause host damages/inflammation in co-infections. These promising results urge for rapid 
implementation of studies aiming not only to analyze the possible polymicrobial status of still 
unstudied biofilm-related infections but also focusing on development of specific polymicrobial 
biofilm models. These future studies will certainly help to elucidate molecular mechanisms of bacterial 
interactions that would ultimately lead to the potential identification of molecules or vaccines that can 
target polymicrobial biofilms. 
7.2.3. What Can We Expect from Systems Biology, Computational Biology,  
Ecology or Experimental Evolution? 
Until now, studies of polymicrobial infections using in vivo mammalian models remain scarce 
probably due to the increased complexity to develop such experimental models and the difficulty to 
interpret results coming both from interactions between the microorganisms and the hosts, and 
between microorganisms themselves. Significant progress in this area could be made by integrating 
new concepts and approaches to understand better the ecology of infectious diseases such as the one 
causing gut disorders or leading to lung destruction in CF patients [364,365]. 
In these complex structured ecological systems diseases are predicted to originate from the 
modification of the dynamic of interactions between pathogens, commensal and the hosts systems, and 
to be strongly dependent on the composition of the environment. Computational modeling is a 
common tool used to understand many biological processes, such as epidemiological dynamics [366] 
and emergence of antibiotic resistance [367]. Such approach has allowed genome-scale metabolic 
reconstruction of several pathogens including P. aeruginosa, S. aureus, Burkholderia spp. or 
Salmonella spp. and have been used to predict the behavior of bacteria in complex in vivo modeled 
environments including biofilms leading to the identification of potential target genes or lethal specific 
environment conditions awaiting in vivo validation [368–370]. With metabolic multi-cells modeling, 
taking into account interactions between microorganisms and eukaryotic cells, should come a better 
understanding of potential complex interactions [368]. Efforts have been made to model various 
aspects or properties of biofilms such as, for instance, heterogeneity within biofilms [371] or more 
recently to integrate biofilm formation and development with host dynamics (for example, [372]). 
Indeed, aspects of evolution are also important to integrate to biofilm-related infections because 
outcome of the chronicity of such diseases may result from long lasting interactions and co-evolution 
between microorganisms and hosts. Experimental evolution is a powerful tool that in combination with 
high throughput sequencing technology can help decipher the genetic and molecular basis of 
evolutionary change [373,374]. Such an approach, that has notably been used in medicine to develop 
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attenuated live vaccines [374], has also been successfully used to understand micro-evolution and 
patho-adaptative mutations of P. aeruginosa and B. cenopacia, both in patients and in in vitro or  
in vivo murine models, during modeled or real chronic airway infections. These long-term studies 
identified bacterial functions that can favor persistent life style of these pathogens and that can have 
important clinical implications for management of the disease progression [375–378]. These results 
may also apply to various biofilm-related chronic infections. Thus, specific in vivo models of  
tissue or devices-associated infections could shed light over the various selective pressures acting on 
biofilm physiology and promoting bacterial diversity or the response of biofilm bacteria to different 
antibiotic treatments. 
The world of infectious diseases is today taking a major turn towards the identification and 
integration of the multiple parameters influencing diseases' outcome [364,365,379,380]. A better 
spatial and temporal understanding of dynamic interactions between the microorganisms, the hosts and 
their environment will open a myriad of possibilities for clinicians to perform in the future an adaptive 
management of human infections not solely centered on antibiotics but playing with stability of 
communities or resource competition. Biofilm research has its place to take in this new exciting 
challenge. 
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